Terms: = Ovarian cancer AND TOP2A, TOP2, TP2A AND Treatment
21 results:
1. top2a modulates signaling via the AKT/mTOR pathway to promote ovarian cancer cell proliferation.
Zhang K; Zheng X; Sun Y; Feng X; Wu X; Liu W; Gao C; Yan Y; Tian W; Wang Y
Cancer Biol Ther; 2024 Dec; 25(1):2325126. PubMed ID: 38445610
[TBL] [Abstract] [Full Text] [Related]
2. Rhophilin rho GTPase binding protein 1-antisense RNA 1 (RHPN1-AS1) promotes ovarian carcinogenesis by sponging microRNA-485-5p and releasing DNA topoisomerase II alpha (
Zhou Y; Li J; Yang X; Song Y; Li H
Bioengineered; 2021 Dec; 12(2):12003-12022. PubMed ID: 34787052
[TBL] [Abstract] [Full Text] [Related]
3. Explore the potential molecular mechanism of polycystic ovarian syndrome by protein-protein interaction network analysis.
Chen Q; Zheng B; Du S; Lin Y
Taiwan J Obstet Gynecol; 2021 Sep; 60(5):807-815. PubMed ID: 34507653
[TBL] [Abstract] [Full Text] [Related]
4. The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and top2.
Marzi L; Sun Y; Huang SN; James A; Difilippantonio S; Pommier Y
Mol Cancer Ther; 2020 Aug; 19(8):1589-1597. PubMed ID: 32430490
[TBL] [Abstract] [Full Text] [Related]
5. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
[TBL] [Abstract] [Full Text] [Related]
6. Identification of key biomarkers associated with development and prognosis in patients with ovarian carcinoma: evidence from bioinformatic analysis.
Shen J; Yu S; Sun X; Yin M; Fei J; Zhou J
J Ovarian Res; 2019 Nov; 12(1):110. PubMed ID: 31729978
[TBL] [Abstract] [Full Text] [Related]
7. top2a as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers.
Ghisoni E; Maggiorotto F; Borella F; Mittica G; Genta S; Giannone G; Katsaros D; Sciarrillo A; Ferrero A; Sarotto I; Erriquez J; Di Renzo MF; Aglietta M; Valabrega G
J Ovarian Res; 2019 Feb; 12(1):17. PubMed ID: 30760286
[TBL] [Abstract] [Full Text] [Related]
8. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML
Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102
[TBL] [Abstract] [Full Text] [Related]
9. Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients.
Heestand GM; Schwaederle M; Gatalica Z; Arguello D; Kurzrock R
Eur J Cancer; 2017 Sep; 83():80-87. PubMed ID: 28728050
[TBL] [Abstract] [Full Text] [Related]
10. Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer.
Bai Y; Li LD; Li J; Lu X
J Ovarian Res; 2016 Jun; 9(1):35. PubMed ID: 27315793
[TBL] [Abstract] [Full Text] [Related]
11. Adjuvant chemotherapy in early breast cancer.
Ejlertsen B
Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
[TBL] [Abstract] [Full Text] [Related]
12. Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.
Erriquez J; Olivero M; Mittica G; Scalzo MS; Vaira M; De Simone M; Ponzone R; Katsaros D; Aglietta M; Calogero R; Di Renzo MF; Valabrega G
Oncotarget; 2016 May; 7(18):26181-91. PubMed ID: 27027433
[TBL] [Abstract] [Full Text] [Related]
13. top2a gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: top2a as marker of response to PLD in ovarian cancer.
Erriquez J; Becco P; Olivero M; Ponzone R; Maggiorotto F; Ferrero A; Scalzo MS; Canuto EM; Sapino A; Verdun di Cantogno L; Bruna P; Aglietta M; Di Renzo MF; Valabrega G
Gynecol Oncol; 2015 Sep; 138(3):627-33. PubMed ID: 26100858
[TBL] [Abstract] [Full Text] [Related]
14. Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents.
Zoppoli G; Regairaz M; Leo E; Reinhold WC; Varma S; Ballestrero A; Doroshow JH; Pommier Y
Proc Natl Acad Sci U S A; 2012 Sep; 109(37):15030-5. PubMed ID: 22927417
[TBL] [Abstract] [Full Text] [Related]
15. Sensitivity to top2 targeting chemotherapeutics is regulated by Oct1 and FILIP1L.
Lu H; Hallstrom TC
PLoS One; 2012; 7(8):e42921. PubMed ID: 22900064
[TBL] [Abstract] [Full Text] [Related]
16. treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas.
Zajchowski DA; Karlan BY; Shawver LK
Mol Cancer Ther; 2012 Feb; 11(2):492-502. PubMed ID: 22203729
[TBL] [Abstract] [Full Text] [Related]
17. Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays.
Ju W; Yoo BC; Kim IJ; Kim JW; Kim SC; Lee HP
Oncol Res; 2009; 18(2-3):47-56. PubMed ID: 20066894
[TBL] [Abstract] [Full Text] [Related]
18. Gene expression profiling in response to estradiol and genistein in ovarian cancer cells.
Parker LP; Taylor DD; Kesterson S; Gercel-Taylor C
Cancer Genomics Proteomics; 2009; 6(3):189-94. PubMed ID: 19487548
[TBL] [Abstract] [Full Text] [Related]
19. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors.
L'Espérance S; Popa I; Bachvarova M; Plante M; Patten N; Wu L; Têtu B; Bachvarov D
Int J Oncol; 2006 Jul; 29(1):5-24. PubMed ID: 16773180
[TBL] [Abstract] [Full Text] [Related]
20. Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts.
Bani MR; Nicoletti MI; Alkharouf NW; Ghilardi C; Petersen D; Erba E; Sausville EA; Liu ET; Giavazzi R
Mol Cancer Ther; 2004 Feb; 3(2):111-21. PubMed ID: 14985451
[TBL] [Abstract] [Full Text] [Related]
[Next]